Three-year all-cause mortality in patients with CRC and T2D (comparison between propensity-score matched semaglutide vs other anti-diabetic medications groups)

| Size/Group | Exposure Group | Comparison Group | Exposure Group Cases (Overall Risk) | Comparison Group Cases(Overall Risk) | | HR (95% CI) |
|------------|----------------|------------------|--|--------------------------------------|---|--------------------------|
| 553 | semaglutide | anti-diabetics | 48 (8.7%) | 79 (14.3%) | ├-■ | 0.57 (0.40–0.81) |
| 505 | semaglutide | other GLP-1RAs | 43 (8.5%) | 71 (14.1%) | ├─■ ─┤ | 0.59 (0.40–0.86) |
| 561 | semaglutide | insulin | 48 (8.6%) | 99 (17.6%) | ⊢ ■ | 0.44 (0.31–0.62) |
| 547 | semaglutide | metformin | 48 (8.8%) | 80 (14.6%) | ⊢ ■─ | 0.56 (0.39–0.81) |
| 481 | semaglutide | DPP-4i | 42 (8.7%) | 62 (12.9%) | ├─■ | 0.63 (0.43–0.94) |
| 506 | semaglutide | SGLT2i | 42 (8.3%) | 61 (12.1%) | ⊢ ■ | 0.67 (0.45–0.99) |
| 504 | semaglutide | SU | 46 (9.1%) | 75 (14.9%) | ├─ ■─┤ | 0.59 (0.41–0.85) |
| 325 | semaglutide | TZD | 32 (9.8%) | 54 (16.6%) | ├── | 0.54 (0.35–0.84) |
| | | | | | 0.10 0.20 0.40 0.70 2 Hazard Ratio (Hi | 2.0 3.00 5.00 8.00 R) |